Wenxin Keli,also named as Wenxin Granule/ WXKL or WK.
Wenxin Keli is The First State-sanctioned TCM Herbs-based Antiarrhythmic Drug manufactured by Buchang Pharma since 1995. It has gained:
The No.1 herbs medicine Choice for Afib
The best selling #1 herbs medicine for Arrhythmia.
The best selling #4 herbs medicine for Cardiovascular.
The best selling #5 herbs medicine for CHD and Angina.
The first state-sanctioned traditional Chinese medicine-based antiarrhythmic drug.
Wenxin Keli formula History
Wenxin keli is formulated from Zhigancaotang ,also known as Licorice Decoction to Tonify the Spleen. which was created about 2000 years ago. It’s used primarily to treat heart palpitations, fatigue, and dry mouth. The basic formula is believed to nourish the heart, invigorate the spleen, and restore blood and pulse balance.
The original formula for Zhi Gan Cao Tang consists of six ingredients, In the early 1980s, Dr. Yu-Ping Zhou, together with other TCM doctors from Guang’anmen (GAM) Hospital affiliated with the China Academy of Chinese Medical Sciences (formerly the China Academy of TCM), initiated the research and development of Wenxin Keli. The composition of this formula was determined under the treatment principle of pattern identification in TCM from the prescriptions of Zhigancao tang(prepared licorice root decoction) in Shanghan zabing lun which was created about 2000 years ago. :“Zhigancao tang is mainly used in patients with palpitations due to irregular or intermittent pulses,” and from the personal clinical experience of physicians in GAM Hospital. Then, the preparation form of this formula was changed from decoction to granule.
In 1987, Wenxin Keli for the treatment of arrhythmia became a research project of the Institute of Chinese Medical Sciences. In 1991, it was included in “The 8th Five-Year Plan,” the National Key Science and Technology Project of TCM. In 1996, the outcomes were reviewed and approved. In 1995, this product received new drug certification issued by the Ministry of Health of the people’s Republic of China and was officially marketed.
Wenxin Keli Studies
Since 1995, further in-depth studies on its antiarrhythmic mechanisms of action were carried out at different levels ranging from clinical studies to basic studies and from myocardial tissues to animals. The results confirmed the significant preventive and therapeutic efficacy of Wenxin Granule on arrhythmias induced by aconitine, barium chloride, and epinephrine.Studies on the mechanisms of action then were performed at the cellular and molecular levels. The application of the whole-cell patch-clamp technique proved the followings: Wenxin Keli significantly inhibited sodium, potassium, and calcium channels on myocardial cell membrane in a dose-dependent manner, and it was found to possess activities of Class I, III, and IV antiarrhythmic drugs.
Foreign scholars began to investigate the Wenxin Keli in 2005. Benefiting from the advanced basic research technologies and previously developed equipment, a number of internationally renowned scholars became involved in the study on Wenxin Keli and three important achievements were quickly achieved.
The first is the study conducted by Xue et al.This study confirmed that Wenxin Keli significantly inhibited late sodium currents to reduce early after-depolarization, delayed after-depolarization, and T-wave alternate, thus to prevent and reduce the occurrence of malignant ventricular arrhythmia.
The second is the study conducted by Burashnikov et al. in 2012. This study showed that Wenxin Keli produced atrial-selective inhibition of peak sodium current (INa) and was thus capable of prolonging postrepolarizing refractoriness and prevented or terminated atrial fibrillation induced by acetylcholine and burst pacing. The conclusion was affirmed by a commentary article.
The third is another study conducted by Minoura Y et al. in which Wenxin Keli was found to inhibit the transient outward current Ito. Using experimental models of Brugada syndrome generated with the Ito agonists (NS5806), Wenxin Keli, particularly in combination with quinidine, was shown to suppress the electrocardiographic and arrhythmic manifestations of Brugada syndrome, with the inhibition rate of 60% and 100% by 5 and 10 g/L Wenxin Keli, respectively, suggesting a therapeutic effect of Wenxin Keli on Brugada syndrome.
In 2010–2012, a randomized, double-blinded, placebo- controlled, and multicenter clinical study on Wenxin Keli for the treatment of atrial premature beats and ventricular premature beats was conducted. This study, involving 60 Grade-III medical institutions in China, was led by researchers at Beijing Fuwai Cardiovascular Hospital and enrolled 2400 participants. The results showed that the total effective rate of Wenxin Keli for the treatment of atrial premature beats and ventricular premature beats was 83.6% and 83.0%, respectively. It was also reported to improve heart palpitations, chest tightness, fatigue, and other symptoms. No proarrhythmia was observed; the incidence of adverse reactions was not statistically different from those of the placebo group.
In summary, recent studies have advanced our understanding of the mechanisms of action of Wenxin Keli and its clinical effectiveness.
Wenxin keli is valid for various arrhythmias.especially suitable for tachyarrhythmia.It is the preferred herbs medicine for complicated atrial premature beats and ventricular premature beats in symptomatic patients without organic（functional impairments） heart disease.
There are 2 types and 2 different specifications Wenxin keli[Learn more].